Gallant Therapeutics Launches JEDI Study for Feline Chronic Gingivostomatitis
Gallant Therapeutics, a pioneering biotechnology company in animal health, has announced the initiation of the JEDI study, a pivotal trial to assess the safety and effectiveness of a novel allogeneic stem cell therapy for cats suffering from refractory feline chronic gingivostomatitis (FCGS). This groundbreaking study represents a potential first-in-class therapy for a severe disease that […]